Research programme: bispecific antibodies - MedImmune/Amgen

Drug Profile

Research programme: bispecific antibodies - MedImmune/Amgen

Alternative Names: anti CEA BiTE; anti-CEA antibody; bscEphA2xCD3; EphA2 Bite antibody; EphA2 BiTE Program; EphA2xCD3-bispecific antibody; MEDI-544

Latest Information Update: 09 Mar 2012

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Amgen
  • Class Bispecific antibodies
  • Mechanism of Action Carcinoembryonic antigen inhibitors; Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 07 Mar 2012 Micromet Inc has been acquired by Amgen
  • 31 Jul 2007 Preclinical development is ongoing
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top